CSL Limited (CSLLY)
USD 87.11
(0.13%)
USD 87.11
(0.13%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 12.18 Billion USD | -33.67% |
| 2023 | 12.22 Billion USD | 26.6% |
| 2022 | 9.65 Billion USD | 66.32% |
| 2021 | 5.8 Billion AUD | -3.1% |
| 2020 | 5.99 Billion AUD | 28.52% |
| 2019 | 4.66 Billion AUD | 6.3% |
| 2018 | 4.38 Billion AUD | 10.34% |
| 2017 | 3.97 Billion AUD | 26.47% |
| 2016 | 3.14 Billion AUD | 37.81% |
| 2015 | 2.28 Billion AUD | 20.66% |
| 2014 | 1.89 Billion AUD | 12.59% |
| 2013 | 1.67 Billion AUD | 29.01% |
| 2012 | 1.3 Billion AUD | 192.53% |
| 2011 | 444.86 Million AUD | 13.25% |
| 2010 | 392.81 Million AUD | -32.19% |
| 2009 | 579.28 Million AUD | -36.48% |
| 2008 | 911.95 Million AUD | 6.69% |
| 2007 | 854.75 Million AUD | 8.79% |
| 2006 | 785.7 Million AUD | 0.54% |
| 2005 | 781.48 Million AUD | 31.8% |
| 2004 | 592.93 Million AUD | 52.23% |
| 2003 | 389.49 Million AUD | 7.96% |
| 2002 | 360.77 Million AUD | 12.75% |
| 2001 | 319.98 Million AUD | 12591.09% |
| 2000 | 2.52 Million AUD | -57.78% |
| 1999 | 5.97 Million AUD | -33.22% |
| 1998 | 8.94 Million AUD | -68.53% |
| 1997 | 28.41 Million AUD | -2.77% |
| 1996 | 29.22 Million AUD | -19.53% |
| 1995 | 36.31 Million AUD | 45.24% |
| 1994 | 25 Million AUD | 369.53% |
| 1993 | 5.32 Million AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 12.1 Billion USD | 0.0% |
| 2024 Q1 | 18.68 Billion USD | 52.84% |
| 2024 Q4 | 12.18 Billion USD | 0.0% |
| 2024 FY | 12.18 Billion USD | -0.36% |
| 2023 Q2 | 12.11 Billion USD | -35.55% |
| 2023 Q1 | 18.8 Billion USD | 94.69% |
| 2023 FY | 12.22 Billion USD | 26.6% |
| 2023 Q4 | 12.22 Billion USD | -32.64% |
| 2023 Q3 | 18.15 Billion USD | 49.79% |
| 2022 Q4 | 9.65 Billion USD | -24.55% |
| 2022 Q1 | 7.7 Billion USD | 32.7% |
| 2022 Q2 | 5.56 Billion USD | -27.74% |
| 2022 Q3 | 12.8 Billion USD | 129.86% |
| 2022 FY | 9.65 Billion USD | 66.32% |
| 2021 Q1 | 8.55 Billion USD | -2.01% |
| 2021 Q3 | 7.54 Billion USD | 23.09% |
| 2021 Q4 | 5.8 Billion AUD | -22.99% |
| 2021 FY | 5.8 Billion AUD | -3.1% |
| 2021 Q2 | 6.12 Billion USD | -28.41% |
| 2020 FY | 5.99 Billion AUD | 28.52% |
| 2020 Q3 | 9.61 Billion USD | 71.45% |
| 2020 Q4 | 8.73 Billion AUD | -9.21% |
| 2020 Q1 | 8.31 Billion USD | 78.24% |
| 2020 Q2 | 5.6 Billion USD | -32.51% |
| 2019 FY | 4.66 Billion AUD | 6.3% |
| 2019 Q3 | 6.56 Billion USD | -0.56% |
| 2019 Q1 | 6.43 Billion USD | 46.63% |
| 2019 Q2 | 6.59 Billion USD | 2.61% |
| 2019 Q4 | 4.66 Billion AUD | -28.95% |
| 2018 Q3 | 5.7 Billion USD | -0.01% |
| 2018 FY | 4.38 Billion AUD | 10.34% |
| 2018 Q1 | 5.67 Billion USD | 42.83% |
| 2018 Q2 | 5.7 Billion USD | 0.5% |
| 2018 Q4 | 4.38 Billion AUD | -23.12% |
| 2017 Q2 | 4.89 Billion USD | 6.07% |
| 2017 FY | 3.97 Billion AUD | 26.47% |
| 2017 Q4 | 3.97 Billion AUD | -23.54% |
| 2017 Q3 | 5.19 Billion USD | 6.31% |
| 2017 Q1 | 4.61 Billion USD | 46.68% |
| 2016 Q1 | 4.37 Billion USD | 91.73% |
| 2016 FY | 3.14 Billion AUD | 37.81% |
| 2016 Q3 | 4.08 Billion USD | -3.2% |
| 2016 Q2 | 4.22 Billion USD | -3.47% |
| 2016 Q4 | 3.14 Billion AUD | -23.08% |
| 2015 Q3 | 2.98 Billion USD | 4.94% |
| 2015 FY | 2.28 Billion AUD | 20.66% |
| 2015 Q1 | 2.66 Billion USD | 40.91% |
| 2015 Q2 | 2.84 Billion USD | 6.9% |
| 2015 Q4 | 2.28 Billion AUD | -23.67% |
| 2014 Q1 | 1.91 Billion USD | 14.19% |
| 2014 Q3 | 2.03 Billion USD | 1.58% |
| 2014 Q2 | 2 Billion USD | 4.51% |
| 2014 FY | 1.89 Billion AUD | 12.59% |
| 2014 Q4 | 1.89 Billion AUD | -7.13% |
| 2013 Q1 | - USD | -100.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | 1.6 Billion USD | 0.0% |
| 2013 Q4 | 1.67 Billion AUD | 4.29% |
| 2013 FY | 1.67 Billion AUD | 29.01% |
| 2012 Q4 | 1.3 Billion AUD | 0.0% |
| 2012 FY | 1.3 Billion AUD | 192.53% |
| 2011 Q4 | 444.86 Million AUD | 0.0% |
| 2011 FY | 444.86 Million AUD | 13.25% |
| 2010 FY | 392.81 Million AUD | -32.19% |
| 2010 Q4 | 392.81 Million AUD | 0.0% |
| 2009 Q4 | 579.28 Million AUD | 0.0% |
| 2009 FY | 579.28 Million AUD | -36.48% |
| 2008 Q4 | 911.95 Million AUD | 0.0% |
| 2008 FY | 911.95 Million AUD | 6.69% |
| 2007 Q4 | 854.75 Million AUD | 0.0% |
| 2007 FY | 854.75 Million AUD | 8.79% |
| 2006 FY | 785.7 Million AUD | 0.54% |
| 2006 Q4 | 785.7 Million AUD | 0.0% |
| 2005 FY | 781.48 Million AUD | 31.8% |
| 2005 Q4 | 781.48 Million AUD | 0.0% |
| 2004 Q4 | 592.93 Million AUD | 0.0% |
| 2004 FY | 592.93 Million AUD | 52.23% |
| 2003 Q4 | 389.49 Million AUD | 0.0% |
| 2003 FY | 389.49 Million AUD | 7.96% |
| 2002 FY | 360.77 Million AUD | 12.75% |
| 2002 Q4 | 360.77 Million AUD | 0.0% |
| 2001 Q4 | 319.98 Million AUD | 0.0% |
| 2001 FY | 319.98 Million AUD | 12591.09% |
| 2000 Q4 | 2.52 Million AUD | 0.0% |
| 2000 FY | 2.52 Million AUD | -57.78% |
| 1999 Q4 | 5.97 Million AUD | 0.0% |
| 1999 FY | 5.97 Million AUD | -33.22% |
| 1998 Q4 | 8.94 Million AUD | 0.0% |
| 1998 FY | 8.94 Million AUD | -68.53% |
| 1997 Q4 | 28.41 Million AUD | 0.0% |
| 1997 FY | 28.41 Million AUD | -2.77% |
| 1996 FY | 29.22 Million AUD | -19.53% |
| 1995 FY | 36.31 Million AUD | 45.24% |
| 1994 FY | 25 Million AUD | 369.53% |
| 1993 FY | 5.32 Million AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -29468.235% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -295463.491% |
| SQZ Biotechnologies Company | 27.47 Million USD | -44248.586% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -27988.903% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -40827.682% |
| Mesoblast Limited | 118.7 Million USD | -10163.654% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1284659.315% |
| Genus plc | 233.1 Million USD | -5126.512% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -415646.993% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -906653.876% |
| Marizyme, Inc. | 18.71 Million USD | -64988.841% |
| ContraFect Corporation | 2.88 Million USD | -422774.002% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1624300.0% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -8991906.613% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -842245.292% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -523684.854% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -215210.003% |
| MultiCell Technologies, Inc. | 202.58 USD | -6013920326.498% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -21091.88% |
| EV Biologics, Inc. | 1.49 Million USD | -814952.139% |
| Q BioMed Inc. | 4.1 Million USD | -296324.728% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -36705.535% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1933473.198% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -991709.411% |
| Biomind Labs Inc. | 735.54 Thousand USD | -1656229.618% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | -7001.927% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -93637.052% |
| Skye Bioscience, Inc. | 4.61 Million USD | -263871.784% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -1371760.587% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -8608698.881% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -207408.316% |
| IMV Inc. | 28.88 Million USD | -42079.21% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -47369548.898% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -539357.248% |
| GB Sciences, Inc. | 1.75 Million USD | -692388.576% |
| Alpha Cognition Inc. | 1.22 Million USD | -998202.157% |
| HST Global, Inc. | 98.31 Thousand USD | -12391197.715% |
| Halberd Corporation | 150 Thousand USD | -8121900.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -1222677.812% |
| Resverlogix Corp. | 6.49 Million USD | -187590.649% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -2551313.613% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -4766481.114% |
| argenx SE | 20 Million USD | -60815.0% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -26640.562% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -449672.456% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -119149044.254% |
| Genscript Biotech Corporation | 417.73 Million USD | -2816.417% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -6072695.789% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -508006.855% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -5313235.456% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -17910.773% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -402485.296% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -3386794.999% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -59832.113% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -8195441.324% |
| BioStem Technologies, Inc. | 4.71 Million USD | -258484.625% |
| ONE Bio Corp. | 19.71 Million USD | -61695.521% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -4869554.891% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -4898179.189% |
| Agentix Corp. | 50 Thousand USD | -24365900.0% |
| LadRx Corporation | 33.6 Thousand USD | -36252354.919% |
| Cell Source, Inc. | 9.25 Million USD | -131548.703% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1610973.202% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1610973.202% |
| NovAccess Global Inc. | 2.19 Million USD | -553702.935% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -172151.199% |
| Itoco Inc. | 228.37 Thousand USD | -5334500.244% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -5774517.846% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -244391.27% |
| Kadimastem Ltd | 891.22 Thousand USD | -1366893.333% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -3031635.801% |
| CytoDyn Inc. | 30.07 Million USD | -40407.381% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -2515572.622% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -3462484.589% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -155693.636% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -9945206.122% |
| Rebus Holdings, Inc. | 310 Thousand USD | -3929900.0% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -257181.404% |
| International Stem Cell Corporation | 4.17 Million USD | -291498.851% |
| Bioxytran, Inc. | 1.92 Million USD | -632783.117% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -19519871.801% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -558522.587% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -146400.722% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -141810.309% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -783131.403% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -4545795.522% |
| Neutra Corp. | 54.15 Thousand USD | -22496022.313% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -665637.705% |
| PureTech Health plc | 25.51 Million USD | -47653.998% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -995059.391% |
| IXICO plc | 472.02 Thousand USD | -2580918.298% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -78494.929% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -19466.998% |
| CSL Limited | 12.18 Billion USD | 0.0% |
| Cellectis S.A. | 92.77 Million USD | -13031.557% |